LivaNova (NASDAQ:LIVN) Issues FY24 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY24 earnings guidance on Wednesday. The company provided EPS guidance of $3.05-3.15 for the period, compared to the consensus EPS estimate of $3.00. LivaNova also updated its FY 2024 guidance to 3.050-3.150 EPS.

Wall Street Analyst Weigh In

LIVN has been the topic of several recent analyst reports. Barclays increased their target price on LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a research note on Monday, February 26th. Robert W. Baird lifted their price objective on LivaNova from $58.00 to $66.00 and gave the stock a neutral rating in a report on Thursday. Needham & Company LLC restated a buy rating and set a $72.00 target price on shares of LivaNova in a research note on Wednesday. Mizuho raised their price target on shares of LivaNova from $75.00 to $80.00 and gave the company a buy rating in a report on Thursday. Finally, StockNews.com raised shares of LivaNova from a hold rating to a buy rating in a report on Thursday, April 25th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, LivaNova currently has an average rating of Moderate Buy and an average target price of $66.20.

LivaNova Stock Performance

NASDAQ:LIVN traded up $1.23 on Friday, hitting $64.15. The stock had a trading volume of 891,504 shares, compared to its average volume of 781,875. LivaNova has a 52-week low of $42.75 and a 52-week high of $64.36. The stock has a market cap of $3.47 billion, a price-to-earnings ratio of -106.92 and a beta of 0.92. The company has a quick ratio of 2.51, a current ratio of 3.17 and a debt-to-equity ratio of 0.50. The business’s 50-day simple moving average is $54.57 and its two-hundred day simple moving average is $50.94.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.28. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The company had revenue of $294.90 million for the quarter, compared to the consensus estimate of $278.17 million. During the same quarter last year, the firm posted $0.43 earnings per share. The firm’s revenue was up 12.0% compared to the same quarter last year. As a group, research analysts predict that LivaNova will post 3.01 earnings per share for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.